McCarver DG - Search Results

1

Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.

Zheng YM, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, Rettie AE. Zheng YM, et al. Among authors: mccarver dg. Toxicol Appl Pharmacol. 2003 Jan 15;186(2):119-26. doi: 10.1016/s0041-008x(02)00028-5. Toxicol Appl Pharmacol. 2003. PMID: 12639503

2

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

Hines RN, McCarver DG. Hines RN, et al. Among authors: mccarver dg. J Pharmacol Exp Ther. 2002 Feb;300(2):355-60. doi: 10.1124/jpet.300.2.355. J Pharmacol Exp Ther. 2002. PMID: 11805191 Review.

3

Developmental expression of human hepatic CYP2C9 and CYP2C19.

Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Koukouritaki SB, et al. Among authors: mccarver dg. J Pharmacol Exp Ther. 2004 Mar;308(3):965-74. doi: 10.1124/jpet.103.060137. Epub 2003 Nov 21. J Pharmacol Exp Ther. 2004. PMID: 14634042

4

Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.

Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. Koukouritaki SB, et al. Among authors: mccarver dg. Mol Pharmacol. 2005 Aug;68(2):383-92. doi: 10.1124/mol.105.012062. Epub 2005 Apr 27. Mol Pharmacol. 2005. PMID: 15858076

5

Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6).

Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. Hines RN, et al. Among authors: mccarver dg. J Pharmacol Exp Ther. 2003 Sep;306(3):1210-8. doi: 10.1124/jpet.103.053686. Epub 2003 Jun 26. J Pharmacol Exp Ther. 2003. PMID: 12829732

6

A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake.

McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W. McCarver DG, et al. Toxicol Appl Pharmacol. 1998 Sep;152(1):276-81. doi: 10.1006/taap.1998.8532. Toxicol Appl Pharmacol. 1998. PMID: 9772223

7

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.

McCarver DG, Hines RN. McCarver DG, et al. J Pharmacol Exp Ther. 2002 Feb;300(2):361-6. doi: 10.1124/jpet.300.2.361. J Pharmacol Exp Ther. 2002. PMID: 11805192 Review.

8

Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans.

Whetstine JR, Yueh MF, McCarver DG, Williams DE, Park CS, Kang JH, Cha YN, Dolphin CT, Shephard EA, Phillips IR, Hines RN. Whetstine JR, et al. Among authors: mccarver dg. Toxicol Appl Pharmacol. 2000 Nov 1;168(3):216-24. doi: 10.1006/taap.2000.9050. Toxicol Appl Pharmacol. 2000. PMID: 11042094

9

Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.

Nong A, McCarver DG, Hines RN, Krishnan K. Nong A, et al. Among authors: mccarver dg. Toxicol Appl Pharmacol. 2006 Jul 1;214(1):78-87. doi: 10.1016/j.taap.2005.12.001. Epub 2006 Feb 7. Toxicol Appl Pharmacol. 2006. PMID: 16464483

10

Pharmacogenomics and the future of drug therapy.

Hines RN, McCarver DG. Hines RN, et al. Among authors: mccarver dg. Pediatr Clin North Am. 2006 Aug;53(4):591-619. doi: 10.1016/j.pcl.2006.05.008. Pediatr Clin North Am. 2006. PMID: 16872995 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page